PRILENIA
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.
PRILENIA
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2018-01-01
Address:
Herzliya, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.prilenia.com
Total Employee:
11+
Status:
Active
Contact:
+972-77-5558482
Email Addresses:
[email protected]
Total Funding:
105.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome IPv6 Organization Schema Google Universal Analytics
Similar Organizations
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
SSTKBIO
SSTKBIO is a laboratory that develops early detection and early intervention technology for the tumor.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Wave Life Sciences
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases
Current Advisors List
Current Employees Featured
Founder
Investors List
Sectoral Asset Management
Sectoral Asset Management investment in Series B - Prilenia
Talisman Capital Partners
Talisman Capital Partners investment in Series B - Prilenia
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Prilenia
ALS Investment Fund
ALS Investment Fund investment in Series B - Prilenia
Amplitude Venture Capital
Amplitude Venture Capital investment in Series B - Prilenia
Sands Capital Ventures
Sands Capital Ventures investment in Series B - Prilenia
Morningside Venture Partners
Morningside Venture Partners investment in Series B - Prilenia
Forbion Capital Partners
Forbion Capital Partners investment in Series A - Prilenia
Morningside Venture Investments
Morningside Venture Investments investment in Series A - Prilenia
Sectoral Asset Management
Sectoral Asset Management investment in Series A - Prilenia
Key Employee Changes
| Date | New article |
|---|---|
| 2022-09-29 | Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer |
| 2020-06-03 | Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO |
Official Site Inspections
http://www.prilenia.com Semrush global rank: 4.41 M Semrush visits lastest month: 2.21 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Prilenia"
Meet the Team at Prilenia
Limor also serves as CEO of Prilenia’s Israeli entity, Prilenia Neurotherapeutics Ltd. Limor has more than 20 years of experience in strategy, planning, and operations. Prior to joining Prilenia …See details»
About Prilenia Therapeutics: See Our Story
Founded in 2018 by Michael Hayden, MBChB, PhD, a world-renowned scientist in Huntington’s disease (HD) research, Prilenia is a clinical-stage biotech company focused on the urgent mission of developing novel therapeutics to slow the …See details»
Prilenia - Crunchbase Company Profile & Funding
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with …See details»
Update from Prilenia - Huntington's Disease Youth Organization
Sep 3, 2024 In the meantime, Prilenia will continue having discussions with the U.S. Food and Drug Administration (FDA) and other regulatory agencies about a potential path forward for …See details»
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason …
Sep 19, 2024 NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to …See details»
Prilenia - Funding, Financials, Valuation & Investors - Crunchbase
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Search Crunchbase. ... How much funding has this …See details»
Prilenia - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Prilenia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of Board …See details»
Prilenia Therapeutics Development Ltd. - Drug pipelines, Patents ...
Prilenia’s pridopidine is also a neuroprotective agent, and Implicit Bioscience’s IC14 is an anti-CD14 monoclonal antibody devised to regulate the pathogenic inflammatory responses to …See details»
Prilenia - LinkedIn
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral ...See details»
Community Voices - Prilenia
While in high school, Sarina’s sister encouraged her to attend a camp hosted by the Huntington’s Disease Youth Organization (HDYO). “To be honest I was nervous to go,” Sarina recalled. …See details»
Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief ...
Sep 29, 2022 Prilenia represents an organization truly committed to scientific rigor as well as to people living with serious neurological diseases, like. Prilenia Therapeutics B.V. , a clinical …See details»
Newsroom | Prilenia Therapeutics B.V.
Apr 29, 2024 At Prilenia Therapeutics B.V., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the email alerts …See details»
Prilenia Announces Clinical Data in Support of its Plans to Initiate ...
Jan 19, 2024 Prilenia Therapeutics B.V. , a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative …See details»
For Patients & Families | Prilenia
Prilenia cares deeply about patients and their families impacted by neurodegenerative and neurodevelopmental disorders. We recognize the physical, emotional, and social impact these …See details»
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD …
Mar 28, 2023 Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression ... is a not-for-profit …See details»
Pridopidine Maintains Effectiveness in Huntington Disease Without ...
Apr 14, 2024 New analyses from the phase 3 PROOF-HD trial (NCT04556656) showed that pridopidine (Prilenia Therapeutics), an orally available small molecule and potent sigma-1 …See details»
An Introduction: Prilenia Pipeline & Science
The need continues, so the research continues. Our pipeline and clinical studies represent research into indications for pridopidine, our first-in-class, investigational selective sigma-1 …See details»
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD …
PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 Prilenia Therapeutics B.V., a clinical stage …See details»
Select Publications - Prilenia
Numerous peer-reviewed publications provide insights about pridopidine, an investigational sigma-1 receptor agonist, in neurodegenerative diseases.See details»